Neogenomics Laboratories

NeoGenomics News


Special Announcement


NeoGenomics to attend 2023 ASCO® Annual Meeting

NeoGenomics is thrilled to exhibit at the 2023 ASCO® Annual Meeting taking place June 2 - 6, 2023 in Chicago, Illinois. Experts will be holding Q&A sessions in the NeoGenomics booth #5135 to discuss key data from the abstracts being presented. Topics will include their experience with the RaDaR® assay, a liquid biopsy test for molecular/minimal residual disease (MRD) as well as MultiOmyx™. MultiOmyx is NeoGenomics’ proprietary, multiplexed immunofluorescence platform that enables single-cell quantification and advanced spatial analysis for up to 60 proteins in a single FFPE tissue section.

To learn more or RSVP for one of the presentations, click here.


Test Updates


Effective Monday, June 5th, the PD-L1 SP263 FDA (TECENTRIQ®) for NSCLC test name will be changed to PD-L1 SP263 FDA for NSCLC.

  • This test is now the companion diagnostic (CDx) for a second drug, LIBTAYO® (cemiplimab-rwlc). The FDA approved the label expansion for the VENTANA PD-L1 (SP263) Assay on March 6, 2023.
  • Test results will now refer to both therapies and their associated cut-offs; ≥ 1% of tumor cells of any intensity for TECENTRIQ® (atezolizumab) and ≥ 50% of tumor cells (TC) of any intensity for LIBTAYO® (cemiplimab-rwlc).


Effective Monday, June 5th, the NeoTYPE® HRD+ Profile test name will be changed to NeoTYPE® HRR Profile.

  • This change will more closely reflect the reporting output of this test which are gene mutations associated with the homologous recombination repair (HRR) pathways, providing information on if cancer has resulted due to the difficulty in repairing this type of DNA damage known as HRD (homologous recombination deficient).
  • Knowing HRR gene mutation status is important for PARP inhibition targeting in a variety of tumor types including breast, ovarian, pancreatic, and prostate.

Test requisitions will reflect both of these test name changes in the next revision update scheduled for the July timeframe.


Folate receptor alpha (FRα) is a new actionable biomarker in ovarian cancer.

NeoGenomics offers the FOLR1 IHC test. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.

To support physicians in determining FR
α expression in their ovarian cancer patients, ImmunoGen is providing a sponsored, no-charge, third-party IHC testing program for patients with a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer.

To learn more about this program, visit our website.


Interface Updates

For the list of interface-related test changes that will occur on Monday June 5th, click here for a downloadable document to view the impacted interface test codes